Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

BACKGROUND: Overexpression of HER2 is observed in 20 to 30% of breast carcinomas. The use of trastuzumab has improved the treatment of these patients, especially when it is associated with docetaxel. To optimize the use of this treatment, it seems important to select putative complete responders bef...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Esther, Végran, Frédérique, Chevrier, Sandy, Burillier, Laura, Cadouot, Muriel, Lizard-Nacol, Sarab, Coudert, Bruno, Fumoleau, Pierre, Arnould, Laurent, Boidot, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417290/
https://www.ncbi.nlm.nih.gov/pubmed/25879949
http://dx.doi.org/10.1186/s12885-015-1198-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417290/
https://www.ncbi.nlm.nih.gov/pubmed/25879949
http://dx.doi.org/10.1186/s12885-015-1198-9

Ejemplares similares